Monitoring inhibitor patients with the right assays.

Abstract:

:The inhibitor titer is the most important clinical measurement in inhibitor patients, and the Nijmegen method is preferable to the original and well-established Bethesda assay for this purpose; however, both methods have high inter-laboratory variability. Monitoring inhibitor patients after treatment with bypassing agents is difficult. Treatment with recombinant activated factor VII (rFVIIa; NovoSeven, Novo Nordisk, Bagsvaerd, Denmark) can be monitored with assays for FVII clotting activity or with a specific assay for FVIIa; while the latter is more reproducible, its relevance to the clinical response of individual patients remains unclear. Recent years have also witnessed a revival of global assays, which contribute useful additional information and which may be more relevant to the hemostatic state of individual inhibitor patients. One such assay currently undergoing a renaissance is the thrombin generation test (TGT). The TGT has many methodological variations--several of which have been studied in our laboratory--and shows the most promise for use in treatment monitoring. This article reviews the assays most appropriate for monitoring inhibitor patients and discusses some of the most recent developments in the use of global assays in this indication.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

Barrowcliffe TW

doi

10.1053/j.seminhematol.2008.03.002

subject

Has Abstract

pub_date

2008-04-01 00:00:00

pages

S25-30

issue

2 Suppl 1

eissn

0037-1963

issn

1532-8686

pii

S0037-1963(08)00042-5

journal_volume

45

pub_type

杂志文章,评审
  • Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation.

    abstract::Even though the overall outcome after allogeneic transplant has improved significantly in the last decades, late infectious diseases are still the most important causes of late morbidity and mortality. Here, impaired immune reconstitution and therapy of chronic graft-versus-host disease (GVHD) represent the major risk...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.10.009

    authors: Fuji S,Kapp M,Einsele H

    更新日期:2012-01-01 00:00:00

  • High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma.

    abstract::The use of combination chemotherapy has been successful in treating advanced or widespread Hodgkin's disease (HD). For patients with relapsed disease, the long-term prognosis is much poorer, despite the good rate of reinduction into a second or further remission using conventional treatments. The majority of such pati...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Laurence AD,Goldstone AH

    更新日期:1999-07-01 00:00:00

  • Novel agents in development for peripheral T-cell lymphoma.

    abstract::Though peripheral T-cell lymphoma (PTCL) is an area of significant unmet therapeutic need, a number of new treatment options are available for patients, especially those with relapsed or refractory disease. A plethora of drugs are now in development for PTCL, but drugs that truly target novel disease biology are notic...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.01.014

    authors: O'Connor OA

    更新日期:2010-04-01 00:00:00

  • The manufacturing process for recombinant factor IX.

    abstract::Advances in recombinant DNA manufacturing technology have now made possible the production of a highly purified and active recombinant factor IX (rFIX) product. Recombinant factor IX was developed by (1) stable insertion of the genes for both factor IX and PACE-SOL (a truncated, soluble serine protease needed to enhan...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Harrison S,Adamson S,Bonam D,Brodeur S,Charlebois T,Clancy B,Costigan R,Drapeau D,Hamilton M,Hanley K,Kelley B,Knight A,Leonard M,McCarthy M,Oakes P,Sterl K,Switzer M,Walsh R,Foster W

    更新日期:1998-04-01 00:00:00

  • Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma.

    abstract::Both thalidomide and intermittent high-dose dexamethasone are agents with established activity against multiple myeloma. We summarized our experience with thalidomide alone, and then in combination with dexamethasone, for groups of patients with myeloma resistant or relapsing despite standard treatments. Criteria of r...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2003.09.006

    authors: Alexanian R,Weber D,Anagnostopoulos A,Delasalle K,Wang M,Rankin K

    更新日期:2003-10-01 00:00:00

  • Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself.

    abstract::Tumor cells from patients with B-cell malignancies exhibit a number of immunophenotypic characteristics that may be responsible for their survival. It has been shown, for example, that down-modulation of CD154 (CD40 ligand), which allows B cells to respond to T cells, may account for some of the immune defects of thes...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Nadler LM

    更新日期:1999-10-01 00:00:00

  • Towards molecular diagnosis and targeted therapy of lymphoid malignancies.

    abstract::Gene expression profiling of cancer began as a research tool but is rapidly moving towards clinical application. The diagnostic category of diffuse large B-cell lymphoma (DLBCL) can now be viewed as an amalgam of several different diseases that have distinct gene expression profiles, oncogenic mechanisms, and clinical...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(03)00194-x

    authors: Wiestner A,Staudt LM

    更新日期:2003-10-01 00:00:00

  • Cobalamin deficiency in patients infected with the human immunodeficiency virus.

    abstract::Serum vitamin B12 levels are often low in human immunodeficiency virus (HIV)-infected patients. However, only a few patients appear to have actual vitamin B12 deficiency. A low red cell folate level accompanying the low vitamin B12 level makes the presence of vitamin B12 deficiency more likely. Our experience suggests...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Remacha AF,Cadafalch J

    更新日期:1999-01-01 00:00:00

  • Pentostatin for the treatment of indolent lymphoproliferative disorders.

    abstract::Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Early clinical trials...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.12.005

    authors: Ho AD,Hensel M

    更新日期:2006-04-01 00:00:00

  • Thrombosis and anticoagulation.

    abstract::Most of the major advances in thrombosis research have occurred in the last 50 years, reflecting progress in biomedical sciences and clinical trials methodology. Improved understanding of the mechanisms of thrombogenesis has led to the discovery of a plethora of new antithrombotic agents that target many of the key st...

    journal_title:Seminars in hematology

    pub_type: 历史文章,杂志文章,评审

    doi:

    authors: Hirsh J,Weitz JI

    更新日期:1999-10-01 00:00:00

  • Antibody-targeted therapy for myeloid leukemia.

    abstract::The availability of antibodies reactive with antigens expressed only by hematopoietic cells has provided clinical investigators with new tools for use in developing therapies for acute myeloid leukemia (AML). Studies performed to date have investigated the use of such antibodies in an unmodified state, combined with p...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Appelbaum FR

    更新日期:1999-10-01 00:00:00

  • ZAP-70 and defects of T-cell receptor signaling.

    abstract::The activation, function, and development of peripheral T lymphocytes are dependent on the ability to signal properly through the surface T-cell antigen receptor (TCR)-CD3 complex. Transmission of such signals requires the activation of specific cytoplasmic protein tyrosine kinases (PTK) associated with the TCR. Recen...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Elder ME

    更新日期:1998-10-01 00:00:00

  • Safety profile of recombinant factor VIIa.

    abstract::Recombinant factor VIIa (rFVIIa; NovoSeven(R), Novo Nordisk, Bagsvaerd, Denmark) has been used for many years in the successful management of bleeding episodes in patients with hemophilia and inhibitors. More recently, rFVIIa has also shown considerable success as a hemostatic agent in trauma and surgery patients with...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2003.11.019

    authors: Roberts HR,Monroe DM 3rd,Hoffman M

    更新日期:2004-01-01 00:00:00

  • Surface and cytoskeletal events regulating leukocyte membrane topography.

    abstract::The experiments reviewed here establish that surface components and surface functions can assume predictable, asymmetric patterns within the continuous plasma membranes of mammalian leukocytes. Recent biophysical and morphological studies show that receptor redistribution can occur very rapidly and that a unique geome...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Oliver JM,Berlin RD

    更新日期:1983-10-01 00:00:00

  • Leukocyte-endothelial cell interactions.

    abstract::Mechanisms that support migration of leukocytes have been studied extensively in vitro. The adhesion of neutrophils under conditions of flow at venous shear rates primarily involves members of the selectin family. E-selectin is upregulated by cytokine stimulation of endothelial cells (ECs); P-selectin is upregulated b...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Smith CW

    更新日期:1993-10-01 00:00:00

  • RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM).

    abstract::In this review, we discuss disease-causing alterations of RUNT-related transcription factor 1 (RUNX1), a master regulator of hematopoietic differentiation. Familial platelet disorder with predisposition to myeloid leukemia (FPDMM) typically presents with (1) mild to moderate thrombocytopenia with normal-sized platelet...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2017.04.006

    authors: Schlegelberger B,Heller PG

    更新日期:2017-04-01 00:00:00

  • Anemia of chronic disease.

    abstract::Anemia of chronic disease (ACD) or inflammation may be secondary to infections, autoimmune disorders, chronic renal failure, or malignancies. It is characterized by an immune activation with an increase in inflammatory cytokines and resultant increase in hepcidin levels. In addition, inappropriate erythropoietin level...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.06.006

    authors: Gangat N,Wolanskyj AP

    更新日期:2013-07-01 00:00:00

  • Molecular evaluation of acute myeloid leukemias.

    abstract::Traditionally, acute myeloid leukemia (AML) has been diagnosed and classified based on the morphologic and cytochemical criteria of the French-American-British (FAB) classification system. However, more recent studies have demonstrated that the cytogenetic and molecular genetic abnormalities consistently associated wi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Willman CL

    更新日期:1999-10-01 00:00:00

  • Proteasome inhibition for antibody-mediated allograft rejection.

    abstract::Antibody-mediated rejection (AMR) is a major risk factor for graft loss following kidney transplantation. Traditional anti-humoral therapies provide suboptimal therapy and they do not deplete plasma cells, which are the source of antibody production. Proteasome inhibitors (PI) have been shown to deplete both transform...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2012.04.008

    authors: Sadaka B,Alloway RR,Shields AR,Schmidt NM,Woodle ES

    更新日期:2012-07-01 00:00:00

  • Immune dysregulation in immune thrombocytopenia.

    abstract::Immune thrombocytopenia (ITP) is a bleeding disorder characterized by low platelet counts due to decreased platelet production as well as increased platelet destruction by autoimmune mechanisms. A shift toward Th1 and possibly Th17 cells together with impaired regulatory compartment, including T-regulatory (Tregs) and...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.03.011

    authors: Yazdanbakhsh K,Zhong H,Bao W

    更新日期:2013-01-01 00:00:00

  • What do we learn from immunomodulation in patients with immune thrombocytopenia?

    abstract::Current therapeutic strategies for autoimmune diseases primarily rely on immunosuppression, but global immune suppression results in an increased risk for severe infection and malignancy. In contrast, immuomodulation is another therapeutic approach employing intrinsic or environmental regulators that exert modulatory ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2016.04.009

    authors: Kuwana M

    更新日期:2016-04-01 00:00:00

  • Reducing mortality associated with immediate treatment complications of adult leukemias.

    abstract::Analysis of data from 806 patients with newly diagnosed adult acute myelocytic leukemia (AML) (not including acute promyelocytic leukemia [APL] patients) treated at M.D. Anderson Cancer Center from 1995 through 1999 indicated that among patients entering a particular week of induction therapy, mortality rates were 6%,...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1016/s0037-1963(01)90042-3

    authors: Estey E

    更新日期:2001-10-01 00:00:00

  • Flow cytometry in human leukocyte antigen testing.

    abstract::Stem cell transplantation is a recognized treatment for many hematologic malignancies. Human leukocyte antigen (HLA) testing is a key assessment in the evaluation of potential recipients and selection of the appropriate stem cell donor. Over the past several years, technological advances have moved HLA testing from a ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90052-6

    authors: Bray RA

    更新日期:2001-04-01 00:00:00

  • Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma.

    abstract::Psoralens plus ultraviolet A (UVA) light inactivate viruses and bacteria as well as leukocytes. A system employing the synthetic psoralen compound amotosalen hydrochloride (S-59), in combination with UVA light, is being developed to decontaminate platelet concentrates and plasma in a blood-bank setting. S-59 is a hete...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90118-0

    authors: Wollowitz S

    更新日期:2001-10-01 00:00:00

  • The effect of recombinant human colony-stimulating factors on hematopoietic reconstitution following autologous bone marrow transplantation.

    abstract::The prolonged and severe myelosuppression associated with high-dose chemotherapy and autologous bone marrow transplantation is a major causative factor in patient morbidity and mortality resulting from infection and other causes. The recent molecular cloning, in vitro expression, and formulation of recombinant human c...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:

    authors: Peters WP

    更新日期:1989-04-01 00:00:00

  • Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes.

    abstract::High-dose chemoradiotherapy with allogeneic bone marrow or peripheral blood stem cell transplantation (SCT) is a potentially curative treatment for advanced or poor-prognosis hematological malignancies. This procedure was initially considered as a means to deliver supralethal doses of chemotherapy and radiation for th...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.30909

    authors: Giralt S,Anagnostopoulos A,Shahjahan M,Champlin R

    更新日期:2002-01-01 00:00:00

  • The pathogenesis of chronic immune thrombocytopenic purpura.

    abstract::Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder in which the patient's immune system reacts with a platelet autoantigen(s) resulting in thrombocytopenia due to immune-mediated platelet destruction and/or suppression of platelet production. Platelet membrane proteins, for reasons that are unclea...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2007.11.002

    authors: McMillan R

    更新日期:2007-10-01 00:00:00

  • Improving the safety profile of warfarin.

    abstract::Since warfarin remains the predominate drug administered for long-term anticoagulation, optimizing therapy for maximum antithrombotic effect with minimal bleeding risk continues to challenge clinicians. Genetic differences exist that affect an individual's response to warfarin. The clinician can use genetic informatio...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.34089

    authors: Chai SJ,Macik BG

    更新日期:2002-07-01 00:00:00

  • Myelodysplastic syndromes: From pathogenesis and prognosis to treatment.

    abstract::Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by ineffective hematopoiesis resulting in peripheral cytopenia and by increased progression to acute myelocytic leukemia (AML). With the exception of allogeneic stem cell transplantation, there is generally no curative treatment for these d...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2004.02.002

    authors: Fenaux P

    更新日期:2004-04-01 00:00:00

  • Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.

    abstract::The immunomodulatory drug (IMiD) lenalidomide is a more potent immunomodulator than thalidomide with respect to its effects on cytokine modulation and increased T-cell proliferation. Of all the IMiDs, clinical trial data are most mature for lenalidomide. In phase I studies, dose-limiting toxicities of lenalidomide wer...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.10.004

    authors: Richardson P

    更新日期:2005-10-01 00:00:00